Send me real-time posts from this site at my email

Why BioNTech Was a Sickly Stock on Monday

What happened

BioNTech (NASDAQ: BNTX), the out-of-nowhere German biotech that shot to prominence with the coronavirus vaccine it developed with Pfizer (NYSE: PFE), wasn't having a great Monday. After it released lackluster quarterly results, a great many investors sold out of the company; in midafternoon trading, the stock was down by nearly 11%.

So what

For its second quarter, BioNTech's revenue was just under 3.2 billion euros, or $3.3 billion, while its net profit stood at 1.67 billion euros. Both figures, however, were down considerably from the same quarter of 2021. In that frame, BioNTech's top line was a bit over 5.3 billion euros, and it netted almost 2.79 billion euros in profit.

On a per-share basis, BioNTech earned 6.45 euros ($6.57) in the most recent quarter. Analysts were expecting well more from the high-profile biotech; on average, they were modeling $7.20. Revenue also missed, as those prognosticators' collective estimate was for $3.95 billion.

The numbers of vaccinated individuals in the many jurisdictions where BioNTech-Pfizer's Comirnaty is approved are fairly high just now. So it stands to reason that revenue has declined for the company; unlike for the sprawling Pfizer, the coronavirus vaccine is by far BioNTech's most important revenue source.

Now what

BioNTech did sound an optimistic note for its future, with CFO Jens Holstein saying, "With our initiatives around variant-adapted COVID-19 vaccine candidates, we expect an uptake in demand in our key markets in the fourth quarter of 2022, subject to regulatory approval."

The company proffered guidance for its share of Comirnaty revenue for the entirety of 2022 -- it believes it will earn anywhere from 13 billion euros to 17 billion euros.

10 stocks we like better than BioNTech SE
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

They just revealed what they believe are the ten best stocks for investors to buy right now... and BioNTech SE wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of July 27, 2022

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.


Popular posts

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue